Interleukin-6 receptor antagonists in critically ill patients with Covid-19–preliminary report
…, V Pettilä, E Rademaker, MS Santos, CT Saunders… - Medrxiv, 2021 - medrxiv.org
Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and …
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label …
…, M Lown, O van Hecke, MA Detry, CT Saunders… - The Lancet, 2023 - thelancet.com
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive …
…, MG Patel, D Richards, N Berry, MA Detry, C Saunders… - The Lancet, 2021 - thelancet.com
Background A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …
patients not admitted to hospital, but effectiveness in high-risk individuals is unknown. We …
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial
…, KM Rowan, MS Santos, CT Saunders… - Intensive care …, 2021 - Springer
Purpose To study the efficacy of lopinavir-ritonavir and hydroxychloroquine in critically ill
patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID-19 …
patients with coronavirus disease 2019 (COVID-19). Methods Critically ill adults with COVID-19 …
Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain …
…, LF Reyes, A Sanil, H Saito, MS Santos, CT Saunders… - MedRxiv, 2021 - medrxiv.org
BACKGROUND The interleukin-6 receptor antagonist tocilizumab improves outcomes in
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness of …
critically ill patients with coronavirus disease 2019 (COVID-19). However, the effectiveness of …
[HTML][HTML] Effect of antiplatelet therapy on survival and organ support–free days in critically ill patients with COVID-19: a randomized clinical trial
…, LF Reyes, H Saito, MS Santos, CT Saunders… - Jama, 2022 - ncbi.nlm.nih.gov
Interventions Patients were randomized to receive either open-label aspirin (n= 565), a
P2Y12 inhibitor (n= 455), or no antiplatelet therapy (control; n= 529). Interventions were …
P2Y12 inhibitor (n= 455), or no antiplatelet therapy (control; n= 529). Interventions were …
Inhaled budesonide for COVID-19 in people at higher risk of adverse outcomes in the community: interim analyses from the PRINCIPLE trial
…, MG Patel, N Berry, MA Detry, CT Saunders… - Medrxiv, 2021 - medrxiv.org
BACKGROUND Inhaled budesonide has shown efficacy for treating COVID-19 in the
community but has not yet been tested in effectiveness trials. METHODS We performed a …
community but has not yet been tested in effectiveness trials. METHODS We performed a …
Acute kidney injury and subsequent frailty status in survivors of critical illness: a secondary analysis
…, TD Girard, NE Brummel, CT Saunders… - Critical care …, 2018 - journals.lww.com
Objectives: Acute kidney injury frequently complicates critical illness and is associated with
high morbidity and mortality. Frailty is common in critical illness survivors, but little is known …
high morbidity and mortality. Frailty is common in critical illness survivors, but little is known …
A classical regression framework for mediation analysis: fitting one model to estimate mediation effects
CT Saunders, JD Blume - Biostatistics, 2018 - academic.oup.com
Mediation analysis explores the degree to which an exposure’s effect on an outcome is
diverted through a mediating variable. We describe a classical regression framework for …
diverted through a mediating variable. We describe a classical regression framework for …
Choice of dose level for a randomized clinical trial of low-dose bevacizumab vs laser for type 1 retinopathy of prematurity
…, DK Wallace, RW Beck, CT Saunders… - JAMA …, 2021 - jamanetwork.com
Methods| The study included infants with type 1 ROP and no prior treatment for ROP.
Approval was obtained from each of the 11 institutional review boards at participating sites. 4 …
Approval was obtained from each of the 11 institutional review boards at participating sites. 4 …
